UBS maintains a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $15.00 (from $18.00).

Analyst, Ami Fadia, noted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE